May 12, 2023

Dear Colleagues,

As Nursing week wraps up around the country, I want to echo the sentiments of the American Nurses Association’s assertion: “You Make A Difference.” As a medical oncologist, I may have a slight bias, but I believe oncology nurses are a particularly special group of individuals who truly make a HUGE difference.

As was so often apparent during the pandemic, nurses are always on the front lines of our health battles. Oncology nurses are critical members of our clinical team, often serving as the glue that holds the entire team together. They advocate for patients and their loved ones, and they are the members of the healthcare team who are most consistently by the bedside, delivering hands-on care, and with the patient every step of the way.

We all know firsthand that cancer nursing is not a typical 9-5 job in which people leave work and leave the day’s work behind. Nurses, nurse practitioners, research nurses, clinical nurse specialists, and the other subspecialty nurses within oncology often work very long hours, and even when they are away from work often have their patients and colleagues on their minds. They guide patients through the initial diagnosis, support them through grueling treatments, celebrate their recoveries, and when needed, are by the bedside when patients are at the end of their life’s journey. I have often been struck by the intuitive sense that so many of my nursing colleagues have about how a patient is responding to treatment and when they need a different therapy. Nurses are often the first to recognize when there has been a subtle change that needs attention, and I have learned through years of experience to listen carefully when one of my nursing colleagues disagrees with a plan that I have crafted.

Our nursing colleagues do more than support our patients and their families, they often support the oncologists and other members of the team. In cancer medicine, it truly takes a team to care for patients and provide the very best care, and nurses are vital to the team.

Patients and their loved ones write letters to us at Yale Cancer Center and Smilow about our nurses. The compliments and praise abound. Comments like: “I could never have survived the entire cancer experience were it not for my nurse” are spoken every day and everywhere. Deep thanks from the bottom of my heart, and from the hearts of everyone at YCC/Smilow for the selfless, unparalleled, and simply incredible work that is done by oncology nursing on a daily basis.

None of us – the patients, their families, the doctors, pharmacists, social workers, etc. – can accomplish anything without the support, guidance, and care that our nurses provide.

We celebrate Nursing week every year and are grateful for all that our nurses do for our patients and their families. Thank you all so much for your tireless work and for all you do to make a difference in the lives of our patients and families.

Eric P. Winer, MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Network
None of us—the patients, their families, the doctors, pharmacists, social workers, and others—could imagine doing our jobs without you. With deep gratitude, it is a true pleasure to celebrate all of the nursing professionals in oncology.

Announcements

Barbara A. Ward, MD, Appointed Associate Professor of Surgery
We are pleased to announce the appointment of Barbara A. Ward, MD, to Associate Professor of Surgery (Surgical Oncology) at Yale School of Medicine. Dr. Ward was named Chair of Surgery for Greenwich Hospital in 2021 and has cared for patients with breast cancer at Greenwich Hospital for 23 years. Prior to joining Greenwich Hospital in 2000, Dr. Ward was director of the Breast Center at Yale Cancer Center. She completed her surgical training at Yale New Haven Hospital and a two-year fellowship at the National Cancer Institute. Dr. Ward’s commitment to excellence in patient care and clinical research provides the foundation for Smilow care provided to patients with breast cancer in Greenwich.

Dr. Ward is an advisor for the Breast Cancer Alliance, which partners with Greenwich Hospital to provide mammography and other services to women who have no or little health insurance and provides research grants to support research initiatives at Yale. She also is a member of various professional societies, including American College of Surgeons, American Society of Breast Surgeons, Eastern Surgical Society, New England Surgical Society, and Yale Surgical Society.

Dr. Ash B. Alpert Appointed to Yale Hematology
Yale Hematology is pleased to welcome Ash Alpert, MD, MFA, (pronouns they/them) as an Instructor of Medicine (Hematology). Dr. Alpert recently completed their post-doctoral fellowship (T32) in health services research at the Brown University School of Public Health and will join Yale Cancer Center, Smilow Cancer Hospital, and Abdominal Cancer Treatment to Smilow Cancer Hospital.

New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer

Yale Pathology Research Highlights Challenges of Interpreting PD-L1 Expression With CPS Method

Financial Toxicity of Ovarian Cancer Treatment for Patients
Dr. Alpert received their medical degree from the University of Vermont Larner College of Medicine and completed residency at Cambridge Hospital and fellowship in Hematology and Medical Oncology at the Wilmot Cancer Institute of the University of Rochester Medical Center. Their clinical expertise is focused on the care of patients with lymphoma, with a particular interest in treating people with lymphoma living with HIV, and they will see patients in New Haven.

Dr. Alpert's research investigates community solutions to improving the experiences and outcomes of transgender people with cancer. They received a Young Investigator Award from Conquer Cancer, the American Society for Clinical Oncology (ASCO) Foundation to develop patient-centered and non-stigmatizing gender identity data collection methods to be implemented in oncology settings and investigate the connections between experiences of violence and cancer risk for transgender people. Dr. Alpert is also involved with advocacy efforts nationally including working with national oncology organizations such as the National Comprehensive Cancer Network and ASCO to implement structural changes to improve outcomes for transgender people with cancer.

Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Physicians
Each year, Connecticut Magazine recognizes some of the state’s best physicians, who provide exceptional care for patients, with its annual “Top Doctors” issue. This year’s list includes 81 physicians from Smilow Cancer Hospital and Yale Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in the state. Congratulations to this year’s “Top Doctors” affiliated with Smilow Cancer Hospital and Yale Cancer Center.

Learn More
Caris Precision Oncology Alliance

Yale Cancer Center has joined the Caris Precision Oncology Alliance (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. The Caris Precision Oncology Alliance includes 83 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology.

Learn More

ASCO Reception

Please join Eric Winer, MD, Roy Herbst, MD, PhD, and our colleagues and former fellows and trainees during ASCO for a Dessert Reception on Sunday, June 4 at 8:30pm CST at the Normandie Lounge, Hilton Chicago. All are welcome to attend!

Learn More

Yale Cancer Center Annual Trainee Colloquium

Yale Cancer Center will hold its Sixth Annual Trainee Colloquium on Friday, June 30, 2023. This will be a forum for Yale trainees to highlight their research, exchange ideas, and initiate collaborations. We invite predoctoral MD, PhD, MD-PhD students, postdoctoral associates, postdoctoral fellows, residents, and clinical fellows engaging in cancer research to submit abstracts describing their work.

Abstract Submission Deadline: May 30, 2023

Learn More

Notables

Mathieu Bakhour, MD, PhD, Assistant Professor of Ophthalmology & Visual Science and a member of Yale Cancer Center’s Genetics, Genomics, and Epigenetics Research Program, has been awarded a Department of Defense (DoD) Grant to study the molecular mechanism underlying uveal melanoma progression. This grant, titled, *Dissecting the Role of Polycomb Repressive Complex 1 in Uveal Melanoma Progression*, is a Melanoma Center of Excellence initiative.

Dr. Vaughn joined the Smilow Hospitalist Service in 2022, and excels in the care of medically-complex patients hospitalized with hematologic malignancies. He is board certified in hematology-oncology with advanced training in bone marrow transplant and cell therapy.

Smilow Cancer Hospital launched its Hospitalist Program in July 2021 with five physicians and continues to expand including board-certified hematologists such as Dr. Vaughn. Hospitalists are doctors dedicated to treating hospitalized patients, and are on staff around the clock to coordinate medical care among a team of physicians and specialists. Vital members of a hospitalized patient’s care team, hospitalists also analyze lab results, admit and discharge patients, and communicate with patients and family.

A gorgeous sunrise photo from the healing garden in full spring bloom at Smilow Cancer Hospital!
The National Academy of Sciences announced the election of 120 members in recognition of their distinguished and continuing achievements in original research, including Anna Maria Pyle, PhD, Sterling Professor of Molecular, Cellular, and Developmental Biology, Professor of Chemistry and a member of Yale Cancer Center’s Cancer Immunology Research Program.

Akiko Iwasaki, PhD, Sterling Professor of Immunobiology and of Molecular, Cellular & Developmental Biology and a member of Yale Cancer Center’s Cancer Immunology Research Program, has been selected to receive the 2023 Else Kröner Fresenius Prize for Medical Research, one of the most prestigious honors of its kind. The prize honors Dr. Iwasaki’s "groundbreaking contributions in the areas of ‘diseases of worldwide significance,’" and will support her current and future investigations of long COVID and other chronic and debilitating post-acute infection syndromes.

Christina Holt, MSN, APRN (BC), ACHPN, OCN, has been recognized by The Hastings Center and The Cunniff-Dixon Foundation for Outstanding End-of-Life Care. Christina is a nurse practitioner with the Smilow Cancer Hospital Palliative Care Program. The Hastings Center Cunniff-Dixon Nursing Awards honors nurses for outstanding care provided to patients nearing the end-of-life.

Lieping Chen, MD, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology) and a member of Yale Cancer Center’s Cancer Immunology Research Program, presented the George Adrouny Memorial Lecture at Tulane University on The Coming Era of Tumor-Site Focused Immunotherapy.

Rachel Perry, PhD, Assistant Professor of Medicine (Endocrinology) and of Cellular and Molecular Physiology and a member of Yale Cancer Center’s Cancer Signaling Networks Research Program, has received the Endocrinology and Metabolism Section New Investigator Award from the American Physiological Society.

Jonathan Ortiz, RT(T), MBA, BS, Radiation Therapist at Smilow Cancer Hospital in Greenwich, is presenting today at the Surface Guided Radiation Therapy annual conference on Extended SSD Use in Metastatic Melanoma Treatment – Right Femur.

Yale Cancer Center is pleased to announce the awardees of the Inaugural Cancer Disparities Research Awards. These awards will provide support for projects that are designed to reduce disparities in cancer care, access to treatments, and differences in cancer outcomes in the state of Connecticut and nationally. From a pool of many strong proposals, congratulations to:

Michaela Dinan, PhD: Socioeconomic Disparities in the Etiology of Advanced Breast Cancer
Brinda Emu, MD, and Jessica Lewis, PhD, LMFT: Cancer Outcome Disparities among Patients with HIV and Cancer: Integrated Approach to Address Social Determinants of Health
Leah Ferrucci, PhD, MPH, and Bubu Banini, MD, PhD: Reducing Disparities in Liver Cancer Outcomes in Connecticut

We are proud to announce that Eric Winer, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital, is the recipient of the Peter I. Pressman Award from the New York Metropolitan Breast Cancer Group. He will present the named lecture at the Cosmo Club in New York City on May 2 on, “HER 2+ Breast Cancer: When Will We Eliminate All Mortality.”
Employee Profile: Kathi Mancieri

When an individual is newly diagnosed with a thoracic cancer and needs to be scheduled for surgery, Kathi Mancieri is often the patient’s next point of contact. As the Thoracic Surgery Intake Coordinator, she speaks with patients over the phone to acquire all of their information before they speak with the surgical nurses for scheduling. It can be difficult talking with people who are still accepting their diagnosis says Kathi, but if she can turn their tears into laughter by the end of the phone call, she considers her day complete.

Kathi always wanted to be a nurse but she had trouble with math and science, so she entered fashion school after her high school graduation. However, Kathi’s passion remained in the medical field, so she joined a private practice, supporting its day-to-day operations. Since joining Yale four and a half years ago, Kathi has been with the Thoracic Surgery team, assisting patients who are scheduled to see Dr. Daniel Boffa. She says talking to patients is the best part of her job and she always provides them with reassurance.

“I love all types of patients, and I like to make them feel better," says Kathi. "No matter if they are stoic or crying, I always want to provide them with reassurance. ‘Yes, you were told you have cancer, but stay positive, you are working with amazing doctors, and you will be receiving the best care.’ The patients I speak with are of all ages and moods, but if by the time we are done on the phone they are laughing, it makes me happy that I have given them empathy, comfort, and levity.”

Dana Osso, RN, BSN, Nurse Coordinator, Thoracic Oncology Program, agrees and says, "Kathi is so dedicated to our patients in Thoracic Surgery. As their first point of contact, she has a way of making patients who are going through their worst, feel at ease just by being her charismatic and confident self on the other end of the line. We are so lucky to have her as part of our team.”

“For patients, the first contact with our program really sets the tone for the entire patient experience,” said Daniel Boffa, MD, Professor of Thoracic Surgery. "We are so grateful for Kathi’s dedication and support to our patients.”

---

We are excited to announce our annual pediatric survivors celebration, Together Towards Tomorrow: A Futuristic Celebration of Survivorship, open to survivors of all ages and their families, is taking place on Sunday, June 11 from 12:00-3:00pm at The Carriage House at Edgerton Park, Hamden. Rain or shine, we’ll be celebrating 70 years of the Tommy Fund for Childhood Cancer and 20 years of the Yale HEROS Clinic!

---

Congratulations to the Breast Friends Fund! The organization’s annual Taste the Cure 2023 raised over $184,000 in support of Metastatic Breast Cancer Research at Smilow Cancer Hospital and Yale Cancer Center led by Dr. Eric Winer, director of Yale Cancer Center.

From left to right: Amanda Cassanelli, Eric Winer, MD, Sandy Cassanelli, Craig Cassanelli and Samantha Cassanelli

Thank you for your continued support!
entire patient experience," said Daniel Boffa, MD, Professor of Thoracic Surgery and Division Chief of Thoracic Surgery. "More often than not, patients are terrified by their diagnosis and confused by all of the tests and consultations. Kathy has guided so many of our patients through this process with skill and kindness. I've had many patients tell me that she was one of the most important parts of the experience and how thankful they were that she was on our team."

---

**Recent Publications**


The Oncologist. 2023 Apr 29.

Read More


Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.

Blood. 2023 Apr 27.

Read More


Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

JAMA Oncology. 2023 Apr 27.

Read More


Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.

Leukemia. 2023 May.

Read More


DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.

American Journal of Hematology. 2023 May.

Read More


The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas.


Read More


Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.

Cancer Medicine. 2023 May 3.

Read More

Endocrinology Clinical Dilemma

May 12, 12:00 PM

Boyer Center for Molecular Medicine, 206/208

Carolina Gonzalez-Lopez, Clinical Fellow

Learn More

Harnessing pyrimidine synthesis dependency to target ARID1A-mutated cancer

May 12, 1:00 PM

Gloria Huang, MD, FACOG

Learn More

Yale Cancer Answers: Melanoma/Skin Cancer Awareness Month

May 14, 7:30 PM

Christine Ko, MD

Learn More

Colorectal Cancer Scientific Retreat 2023

May 16, 10:00 AM

Learn More

Calendar
Funding and Award Opportunities

NCCN, Pfizer and Myovant RFP: Combination Therapy with Relugolix in the Treatment of Advanced Prostate Cancer
NCCN® is pleased to announce a collaboration with Pfizer Global Medical Grants and Myovant Sciences to offer a new grant opportunity. They are seeking proposals for investigator-initiated research to support clinical research studies to further evaluate the effectiveness of relugolix in combination with other therapies for the treatment of advanced prostate cancer.
Application Deadline: May 22, 2023
Read More

Yale Head and Neck SPORE (YHN-SPORE) Career Enhancement Program (CEP)
The CEP of the Yale Head and Neck SPORE has been established to educate the next generation of investigators committed to translational research in head and neck cancer. The CEP will provide support to promising junior investigators and/or establish investigators who have not previously conducted head and neck cancer focused research.
Full applications Due: Friday, May 26, 2023
Submit here

Yale Head and Neck SPORE (YHN-SPORE) Developmental Research Program (DRP)
The Yale Head and Neck SPORE’s DRP provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full YHN-SPORE project or to generate preliminary data or evidence of collaboration for other new NIH grant applications.
Full applications Due: Friday, May 26, 2023
Submit here

DoD Ovarian Cancer Research Program
The Ovarian Cancer Research Program (OCRP) is currently accepting applications for five award mechanisms.
- Clinical Trial Award: supports rapid implementation of clinical trials with the potential to have a significant impact on ovarian cancer. Pre-proposal due: May 26, 2023
- Clinical Translational Research Award: supports correlative studies that address translational research in high-impact or unmet needs in ovarian cancer and have a clinical emphasis. Pre-proposal due: May 26, 2023
Read More

Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01)
Through this NOFO, the NCI intends to establish collaborations between liver cancer investigators and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded Liver Cirrhosis Network (LCN) members to advance our understanding of hepatocellular carcinoma (HCC) as the result of liver cirrhosis and its etiologic risks, development, progression, early diagnosis, and treatment.
Application Deadline: June 2, 2023
Read More

Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in partnership with Pelotonia & AACR
May 16, 7:00 PM
Hope Memorial Building, 216
Michael Cecchini, MD | Rosa Munoz Xicola, PhD | Xiaomei Ma, PhD | Noah Palm, PhD | Siyuan (Steven) Wang, PhD | Sajid A Khan, MD, FACS, FSSO | Michael Chiorazzi, MD, PhD | Joanna Gibson, MD, PhD | Kiran Turaga, MD, MPH | Xavier Llor, MD, PhD | Michaela Dinan, PhD | Kaelyn Sumigray, PhD | Jun Lu, PhD | Caroline Johnson, PhD | Kurt Schalper, MD, PhD | Anne Mongiu, MD, PhD | Kimberly L. Johung, MD, PhD
Learn More

Cancer Genetics and Prevention Program Seminar
May 18, 2:30 PM
Jennifer Doherty, MS, CGC
Learn More

Pharmacology Arnold Welch Lecture Series
May 18, 4:00 PM
Melanie Cobb
Learn More

Center for GI Cancers Seminar Series 2022-2023
May 18, 4:15 PM
Learn More

YCC/Smilow Town Hall
May 18, 5:00 PM
Kevin Billingsley, MD, MBA | Kim Slusser, RN, MSN | Daniel Alexa, MBA | Jensa Morris, MD | Cece Calhoun, MD, MPHS, MBA | Tracy Carafeno, RN, MS, CMNL
Learn More

Urology Grand Rounds
May 19, 7:30 AM
Sterling Hall of Medicine, SHML 221A
Learn More

Yale Cell Biology Seminar
May 19, 9:00 AM
Sterling Hall of Medicine, C-Wing, SHM C-428
Unconventional signaling of CD28 and CTLA4: when their ligands get on T cells
Enfu Hui, PhD
Learn More

Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in partnership with Pelotonia & AACR
May 16, 7:00 PM
Hope Memorial Building, 216
Michael Cecchini, MD | Rosa Munoz Xicola, PhD | Xiaomei Ma, PhD | Noah Palm, PhD | Siyuan (Steven) Wang, PhD | Sajid A Khan, MD, FACS, FSSO | Michael Chiorazzi, MD, PhD | Joanna Gibson, MD, PhD | Kiran Turaga, MD, MPH | Xavier Llor, MD, PhD | Michaela Dinan, PhD | Kaelyn Sumigray, PhD | Jun Lu, PhD | Caroline Johnson, PhD | Kurt Schalper, MD, PhD | Anne Mongiu, MD, PhD | Kimberly L. Johung, MD, PhD
Learn More
This funding opportunity is for female investigators researching breast and gynecologic cancers that focus on prevention, detection, diagnostic, and treatment innovations for breast and gynecologic cancers and advancing outcomes for cancer health disparities. Proposals focused on cancer health disparities and applicants belonging to racial or ethnic groups shown to be underrepresented in the cancer-related sciences workforce are especially encouraged.

**Application Deadline:** June 7, 2023

**Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities (R01)**
As part of the ADVANCE: Advancing Prevention Research for Health Equity program, the NIH Office of Disease Prevention (ODP) within the Office of the Director Division of Program Coordination, Planning, and, Strategic Initiatives (DPCPSI) is soliciting revision applications (formerly called "competitive revisions") to active R01 grants to support studies that develop and evaluate menthol cigarette smoking cessation and prevention interventions for populations that experience health disparities.

**Application Deadline:** June 19, 2023

**AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances Through Research Training (START) Grant**
These grants, which will provide support to postdoctoral or clinical research fellows who are females or are from underrepresented groups, combine research experiences in both academic and industry settings, following a research timeline that will be of greatest benefit to the proposed work. The training provided through this grants program will be invaluable to young investigators by providing fellows with a comprehensive research experience that will make them highly desirable to potential employers in either academic research or the pharmaceutical industry.

**Application Deadline:** June 21, 2023

**MMRF 2023 Research Fellows Award Program**
Supporting early career researchers at the post-doctorate, medical fellow, or junior faculty levels currently active or interested in research in multiple myeloma. The goal of this initiative is to engage and support early career investigators interested in basic and clinical research focused on myeloma and its precursor conditions, with the goal of advancing our understanding of myeloma disease biology, disease risk, and treatment response and relapse.

**Application Deadline:** June 23, 2023

**Integrating Health Disparities into Immuno-Oncology (HDIO) (P20)**
Through this FOA, the NCI intends to support planning and feasibility studies to integrate cancer health disparities into immuno-oncology research studies. This FOA is expected to enable complementary, multi-disciplinary research teams to address interdisciplinary research to integrate cancer health disparities into immuno-oncology research. It is anticipated these feasibility or pilot studies will support the exploration of novel or high-risk research hypotheses.

**Application Deadline:** June 30, 2023

**Addressing the Primary Care Needs of Cancer Survivors (U01)**
The purpose of this FOA is to support the development and testing of primary care practice (PCP)- and health system-level interventions and strategies to promote high quality care for adult cancer survivors during and/or after cancer treatment. The overall goal of this opportunity is to support high quality care for cancer survivors that integrates primary care from the point of diagnosis forward.

**Application Deadline:** July 24, 2023
Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01)
The purpose of this NOFO is to solicit research to better understand the mechanisms of persistent oral human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection as well as its role in the induction and pathogenesis of HPV-associated oropharyngeal cancers (HPV-OPC).

Application Deadline: July 24, 2023

DoD Prostate Cancer Research Program Funding Opportunities for FY23

- Early Investigator Research Award (EIRA) - supports research opportunities focused on prostate cancer for individuals in the early stages of their careers. LOI Due: August 3, 2023
- Exploration – Hypothesis Development Award (EHDA) - supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer. LOI Due: June 22, 2023
- Idea Development Award (IDA) - supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY23 PCRP Overarching Challenges. LOI Due: June 29, 2023
- Physician Research Award (PRA) - supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. LOI Due: August 3, 2023

R50 NCI Specialist - Clinician Scientist - Clinical Trial Not Allowed (PAR-21-306)
Through this FOA, the NCI invites applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants.

Internal Submission Deadline: August 3, 2023

NIH Institutional Excellence in Diversity, Equity, Inclusion, and Accessibility in Biomedical and Behavioral Research Prize Competition
The prize competition goals are as follows:
1. To recognize and reward institutions whose biomedical, social, and behavioral science schools, departments, centers, or divisions have identified gaps with respect to diversity, equity, inclusion, and accessibility (DEIA) and have designed, implemented, and evaluated interventions to address these gaps to achieve sustained improvement in DEIA within their faculty, postdoctoral scholars, and student bodies.
2. To identify effective practices for enhancing DEIA within faculty, postdoctoral scholars, and student bodies that are feasible and can be
Application Deadline: September 26, 2023

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

Unsubscribe renee.gaudette@yale.edu
Update Profile | Constant Contact Data
Notice

Sent by renee.gaudette@yale.edu
powered by Constant Contact
Try email marketing for free today!